Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.


Stock Analysis, IPO, Mutual Funds, Bonds & More

Buy Aarti Drugs, target Rs 796: Anand Rathi

Aarti Drugs is a smallcap company, operating in pharmaceuticals and health care sector.|
Updated: Jun 19, 2019, 02.12 PM IST
Getty Images
The brokerage has set a one-year horizon for the stock to hit the target price.
Anand Rathi has given a buy recommendation on Aarti Drugs with a target price of Rs 796.

Shares of Aarti Drugs traded at Rs 531 around 2 pm on 19 June, 2019. The brokerage has set a one-year horizon for the stock to hit the target price.

The company’s API range covers therapies such as antibiotics, anti-inflammatories, cardioprotectants, anti-diarrhoeals, anti-fungals, anti-diabeties, etc. Capacities have been recently added in all these, except antibiotics.

The company will become the largest producer of Metformin once issues with the technology to produce on a large scale are solved.

It now manufactures 550-600 tonnes a month, whereas after the technology is in place it will manufacture 1,000 tonnes a month.

Ciprofloxacin, which is one of its top 10 products, has a 40-50 per cent global market share; growth, though, has been flat.

The company plans to push growth by capturing competitors’ market shares.

Considering the new capacities and volume growth, the brokerage expects a 15 per cent revenue CAGR in APIs over FY19-21.

To boost its formulations business, the company acquired Pinnacle Life Sciences in 2015. At present, this comprises a small part of its business (9.6 per cent of sales).

The company has filed dossiers in Europe and in emerging markets in the last few years. The brokerage expects this business to clock a 12 per cent revenue CAGR over FY19-21.

"We expect the operating margins to expand 192bps by FY21, with a 22.5 per cent Ebitda CAGR over FY19-21, supported by stabilising raw material prices and a better product mix," said the brokerage.

It expect the company's revenue and PAT to clock 14.5 per cent and 32 per cent CAGRs, respectively, over FY19-21.

The brokerage retained buy rating, with an unchanged price target of Rs 796, based on 12 times FY21E earnings per share (EPS).

Delay in the ramp-up of the recently-added capacity and more-than-expected competition in generic APIs are the risk factors for the stock, the broekerage said.

Also Read

Anand Rathi initiates coverage on Arvind Fashions, target price of Rs 554

Hold Greenply Industries, target Rs 172: Anand Rathi

Anand Rathi retains buy on Dilip Buildcon, target price Rs 586

Sell Mindtree, target Rs 910: Anand Rathi

Anand Rathi maintains ‘buy’ on KPIT Tech, target price Rs 135

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Disclaimer: This recommendation is analyst's own and does not represent those of & Please consult your financial advisor before taking any position in the stock/s mentioned.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service